A retrospective study of the treatment of locally advanced prostate cancer by six institutions in eastern and north-eastern Japan

BJU International

Volumn 95, Issue 4, 2005, Pages 534-540

  Hachiya, Takahiko ^a,g   Akakura, Koichiro ^b   Saito, Shiro ^c   Shinohara, Nobuo ^d   Sato, Kazunari ^e   Harada, Masaoki ^f   Kato, Tetsuro ^e   Okada, Kiyoki ^a  

^a NIHON UNIVERSITY   (Japan)

^b CHIBA UNIVERSITY   (Japan)

^c KEIO UNIVERSITY   (Japan)

^d HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e AKITA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f KANAGAWA CANCER CENTER   (Japan)

^g NONE   (Japan)

Author keywords

Hormone therapy; Locally advanced prostate cancer; Radical prostatectomy; Radiotherapy

Indexed keywords

ANTIANDROGEN; ESTROGEN; PROSTATE SPECIFIC ANTIGEN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CASTRATION; CHI SQUARE TEST; CLINICAL FEATURE; CLINICAL PROTOCOL; HISTOPATHOLOGY; HUMAN; JAPAN; KRUSKAL WALLIS TEST; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RANK SUM TEST; RETROSPECTIVE STUDY; STATISTICAL ANALYSIS; SURVIVAL RATE;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; BRACHYTHERAPY; HUMANS; JAPAN; MALE; MIDDLE AGED; NEOPLASM STAGING; PRACTICE GUIDELINES; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; QUALITY OF LIFE; RETROSPECTIVE STUDIES; RISK FACTORS; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 14644438647     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2005.05334.x     Document Type: Article

References (27)

1. Poppel HV, Ridder DD, Eligamal AA et al. Neoadjuvant hormonal therapy before radical prostatectomy decreases the number of positive surgical margins in stage T2 prostate cancer: Interim results of a prospective randomized trial. J Urol 1995; 154: 429-34
2. Soloway MS, Sharifi R, Wajsman Z, McLeod D, Wood DP Jr, Puras-Baez A. Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2b:NxM0) prostate cancer. J Urol 1995; 154: 424-8
3. Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Eng J Med 1999; 341: 1781-8
4. Bolla M, Gonzalez D, Warde P et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997; 337: 295-300
5. Akakura K, Isaka S, Akimoto S et al. Long-term results of a randomized trial for the treatment of stages B2 and C prostate cancer: radical prostatectomy versus external beam radiation therapy with a common endocrine therapy in both modalities. Urology 1999; 54: 313-8
6. Roach M, Lu J, Pilepich MV et al. Predicting long-term survival, and the need for hormonal therapy: a meta-analysis of RTOG prostate cancer trials. Int J Radiat Oncol Biol Phys 2000; 47: 617-27
7. Horwitz EM, Winter K, Hanks GE, Lawton CA, Russell AH, Machtay M. Subset analysis of RTOG 85-31 and 86-10 indicates an advantage for long-term vs. short-term adjuvant hormones for patients with locally advanced nonmetastatic prostate cancer treated with radiation therapy. Int J Radiat Oncol Biol Phys 2001; 49: 947-56
8. Pilepich MV, Winter K, John MJ et al. Phase V radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001; 50: 1243-52
9. Akaza H, Homma Y, Okada K et al. A prospective and randomized study of primary hormonal therapy for patients with localized or locally advanced prostate cancer unsuitable for radical prostatectomy: results of the 5-year follow-up. BJU Int 2003; 91: 33-6
10. Van den Ouden D, Schroder FH. Management of locally advanced prostate cancer. Staging, natural history, and results of radical surgery. World J Urol 2000; 18: 194-203
11. Lerner SE, Blute ML, Zincke H. Extended experience with radical prostatectomy for clinical stage T3 prostate cancer, outcome and contemporary morbidity. J Urol 1995; 154: 1447-52
12. Van Poppel H, Goethuys H, Callewaert P, Vanuytsel L, Van de Voorde W, Baert L. Radical prostatectomy can provide a cure for well-selected clinical stage T3 prostate cancer. Eur Urol 2000; 38: 372-9
13. International Union Against Cancer; Sobin LH, Wittekind CH eds. TNM Classification of Malignant Tumors. 5th edn. New York: John Wiley & Sons, 1997: 170-3
14. Aus G, Abbou CC, Pacik D et al. EAU guidelines on prostate cancer. Eur Urol 2001; 40: 97-101
15. Baker LH, Bahnson RR, Hanks GE et al. NCCN practice guidelines for prostate cancer. Oncology 2000; 14: 111-9
16. Soloway MS. Controversies in the management of clinically localized prostate cancer. In Belldegrun A, Kirby RS, Oliver RTD eds, New Perspectives in Prostate Cancer. Oxford UK: ISIS Medical Media, 1998: 206-10
17. Arai Y, Egawa S, Tobisu K et al. Radical retropubic prostatectomy. Time trends, morbidity and mortality in Japan. BJU Int 2000; 85: 287-94
18. Cookson MS, Sogani PC, Russo P et al. Pathological staging and biochemical recurrence after neoadjuvant androgen deprivation therapy in combination with radical prostatectomy in clinically localized prostate cancer: result of a phase II study. Br J Urol 1997; 79: 432-8
19. Scolieri MJ, Altman A, Resnick MI. Neoadjuvant hormonal ablative therapy before radical prostatectomy: a review. Is it indicated? J Urol 2000; 164: 1465-72
20. Andriole GL Adjuvant therapy for prostate cancer patients at high risk of recurrence following radical prostatectomy. Eur Urol 1997; 32 (Suppl. 3): 65-9
21. Cheng WS, Frydenberg M, Bergstralh EJ, Larson-Keller JJ, Zinke H. Radical prostatectomy for pathologic stage C prostate cancer. Influence of pathologic variables and adjuvant treatment on disease outcome. Urology 1993; 42: 283-91
22. Beyer A, Leitenberger A, Altwein JE. Adjuvant hormonal therapy following radical prostatectomy. Eur Urol 1993; 24 (Suppl. 2): 51-6
23. Zietman AL, Prince EA, Nakfoor BM, Shipley WU. Neoadjuvant androgen suppression with radiation in the management of locally advanced adenocarcinoma of the prostate: Experimental and clinical results. Urology 1997; 49: 74-83
24. Fowler JR Jr, Bigler SA, Kolski JM et al. Early results of a prospective study of hormone therapy for patients with locally advanced prostate carcinoma. Cancer 1998; 82: 1112-7
25. Fowler JE Jr, Bigler SA, White PC, Duncan WL. Hormone therapy for locally advanced prostate cancer. J Urol 2002; 168: 546-9
26. Watanabe M, Nakayama T, Shiraishi T, Stemmermann GN, Yatani R. Comparative studies of prostate cancer in Japan versus the United States. Urol Oncol 2000; 5: 274-83
27. Magee PJ, Rowland IR. Phytooestrogens, their mechanism of action: current evidence for a role in breast and prostate cancer. Br J Nutr 2004; 91: 513-31